Effectiveness of activated factor VII in postoperative bleeding after cardiac surgery with extracorporeal membrane oxygenation;Eficacia del factor VII activado en la hemorragia poscirugía cardíaca y oxigenación con membrana extracorpórea

Anales de Pediatria

Volumn 62, Issue 5, 2005, Pages 471-474

  Lopez Herce Cid J ^a   Arriola Pereda, G ^a   Zunzunegui Martinez J L ^a   Brandstrup Azuero, K B ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Cardiac surgery; Children; Coagulopathy; ECMO; Factor VIIa; Postoperative bleeding

Indexed keywords

BLOOD CLOTTING FACTOR 7; FRESH FROZEN PLASMA; RECOMBINANT ACTIVATED FACTOR 7; RECOMBINANT BLOOD CLOTTING FACTOR 7A; UNCLASSIFIED DRUG;

ARTICLE; BLEEDING; CASE REPORT; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EXTRACORPOREAL OXYGENATION; FEMALE; HEART SURGERY; HEART TRANSPLANTATION; HUMAN; POSTOPERATIVE HEMORRHAGE; PRESCHOOL CHILD; SIDE EFFECT; THROMBOCYTE TRANSFUSION; TUBE;

EID: 20444500425     PISSN: 16954033     EISSN: None     Source Type: Journal    
DOI: 10.1157/13074622     Document Type: Article

References (20)

1. Egan JR, Lammi A, Schell DN, Gillis J, Nunn GR. Recombinant activated factor VII in paediatric cardiac surgery. Intensive Care Med. 2004;30:682-5.
2. Herbertson M. Recombinant activated factor VII in cardiac surgery. Blood Coagul Fibrinolysis. 2004;15 Supl:31-2.
3. Hedner U. Novoseven as a universal haemostatic agent. Blood Coagul Fibrinolysis 2000;11 Supl 1:107-11.
4. Kennett G, Abshire T. Recombinant factor VIIa: review of efficacy, dosing regiments and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost. 2004;2:899-909.
5. Veldman A, Fischer D, Voigt B, Beyer PA, Schlosser R, Allendorf A, et al. Life-threatening hemorrhage in neonates: management with recombinant activated factor VII. Intensive Care Med. 2002;28:1635-7.
6. Karadimov D, Binev K, Nachkov Y, Platikanov V. Use of activated recombinant Factor VII (NovoSeven) during neurosurgery. J Neurosurg Anesthesiol. 2003;15:330-2.
7. Eikelboom JW, Bird R, Blythe D, Coyle L, Gan E, Harvey M, et al. Recombinant activated factor VII for the treatment of life-threatening haemorrhage. Blood Coagul Fibrinolysis. 2003;14: 713-7.
8. Blatt J, Gold SH, Wiley JM, Monahan PE, Cooper HC, Harvey D. Off-label use of recombinant factor VIIa in patients following bone marrow transplantation. Bone Marrow Transplant. 2001;28:405-7.
9. Markiewicz M, Kalicinski P, Kaminski A, Laniewski P, Ismail H, Drewniak T, et al. Acute coagulopathy after reperfusion of the liver graft in children correction with recombinant activated factor VII. Transplant Proc. 2003;35:2318-9.
10. Poon MC, d'Oiron R. Recombinant activated factor VII (NovoSeven) treatment of platelet-related bleeding disorders. International Registry on Recombinant Factor VIIa and Congenital Platelet Disorders Group. Blood Coagul Fibrinolysis. 2000; 11 Suppl 1:S55-68.
11. Chuansumrit A, Nuntnarumit P, Okascharoen C, Teeraratkul S, Suwansingh S, Supapannachart S. The use of recombinant activated factor VII to control bleeding in a preterm infant undergoing exploratory laparotomy. Pediatrics. 2002;110:169-71.
12. Mathew P, Winter SS, Frost JD, Hanrahan J, Schwartz M, Jones JE. Novel applications of recombinant factor VIIa for the management of pediatric coagulopathic diseases. J Pediatr Hematol Oncol. 2003;25:499-502.
13. Pychynska-Pokorska M, Moll JJ, Krajewski W, Jarosik P. The use of recombinant coagulation factor VIIa in uncontrolled postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass. Pediatr Crit Care Med. 2004;5:246-50.
14. Tobias JD, Berkenbosch JW, Russo P. Recombinant factor VIIa to treat bleeding after cardiac surgery in an infant. Pediatr Crit Care Med. 2003;4:49-51.
15. Leibovitch L, Kenet G, Mazor K, Matok I, Vardi A, Barzilay Z, et al. Recombinant activated factor VII for life-threatening pulmonary hemorrhage after pediatric cardiac surgery. Pediatr Crit Care Med. 2003;4:444-6.
16. Verrijckt A, Proulx F, Morneau S, Vobecky S. Activated recombinant factor VII for refractory bleeding during extracorporeal membrane oxygenation. J Thorac Cardiovasc Surg. 2004;127: 1812-3.
17. Bui JD, Despotis GD, Trulock EP, Patterson GA, Goodnough LT. Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII. J Thorac Cardiovasc Surg. 2002; 124:852-4.
18. Friederich PW, Henny CP, Messelink EJ, Geerdink MG, Keller T, Kurth KH, et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: A double-blind placebo-controlled randomized trial. Lancet. 2003;361:201-5.
19. Villar A, Aronis S, Morfini M, Santagostino E, Auerswald G, Thomsen HF, et al. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia. 2004;10:352-9.
20. Roberts HR, Monroe DM 3rd, Hoffman M. Safety profile ofrecombinant factor VIIa. Semin Hematol. 2004;41 Supl 1:101-8.